Physician profile
Richard Ford
NPI 1235154667
$2,063.57
in general payments reported to CMS, 2019-2025
18 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $445 · 2021: $295 · 2022: $226 · 2023: $308 · 2024: $182 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.12 | 2021-2024 | |
| Allergan, INC. | $327.32 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $314.55 | 2019-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $210.30 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $188.82 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $116.49 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $84.22 | 2020-2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $58.07 | 2019 | |
| Lundbeck LLC | $56.97 | 2019 | |
| Ironshore Pharmaceuticals INC. | $52.33 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.87 | 2021-2022 | |
| Corium, LLC | $41.63 | 2023-2025 | Azstarys |
| Shire North American Group INC | $39.79 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.67 | 2019-2021 | |
| Neuronetics, INC. | $29.56 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $24.85 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $22.36 | 2021 | |
| Eisai INC. | $16.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.